BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/17/2021 11:30:04 AM | Browse: 300 | Download: 399
 |
Received |
|
2020-08-15 21:50 |
|
Peer-Review Started |
|
2020-08-15 21:51 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-10-21 18:44 |
|
Revised |
|
2020-11-15 23:00 |
|
Second Decision |
|
2020-11-25 11:54 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-11-29 22:25 |
|
Articles in Press |
|
2020-11-29 22:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-12-08 09:17 |
|
Typeset the Manuscript |
|
2021-01-15 02:24 |
|
Publish the Manuscript Online |
|
2021-01-17 11:30 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Is there a place to optimize thoracic radiotherapy in limited-stage small cell lung cancer after twenty years?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
José Máximo Barros, Manglio Miguel Rizzo, Jorge Oscar Chiozza and Felipe Couñago |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
José Máximo Barros, MD, Staff Physician, Department of Radiation Oncology, Radiotherapy Center, Hospital Universitario Austral, Vidt Oncologia Radiante, Pilar 1629, CABA 1425, Argentina. barrosonco@gmail.com |
| Key Words |
Thoracic radiotherapy; Limited-stage small cell lung cancer; Hyperfractionated; High dose; American Society of Clinical Oncology; Small cell lung cancer |
| Core Tip |
There is a lot of research about the role of thoracic radiotherapy in limited-stage small cell lung cancer looking for the best strategy to improve local control and overall survival. The CONVERT study confirmed, in the contemporary era, the standard 45 Gy in 30 fractions during three weeks, concurrent with chemotherapy after the first cycle. High dose hiperfractionated thoracic radiotherapy in phase II trial, presented during American Society of Clinical Oncology (ASCO) 2020, showed a better 2-year survival and a nonsignificant difference in median overall survival. |
| Publish Date |
2021-01-17 11:30 |
| Citation |
Barros JM, Rizzo MM, Chiozza JO, Couñago F. Is there a place to optimize thoracic radiotherapy in limited-stage small cell lung cancer after twenty years? World J Clin Oncol 2021; 12(1): 1-5 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i1/1.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i1.1 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
